Cargando…
A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD), neuropathic pain (NP), fibromyalgia (FMS), and stress incontinence urinary (SUI). These conditions share parallel pathop...
Autores principales: | Rodrigues-Amorim, Daniela, Olivares, José Manuel, Spuch, Carlos, Rivera-Baltanás, Tania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644852/ https://www.ncbi.nlm.nih.gov/pubmed/33192668 http://dx.doi.org/10.3389/fpsyt.2020.554899 |
Ejemplares similares
-
Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report
por: Spuch, Carlos, et al.
Publicado: (2020) -
Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways
por: Rodrigues-Amorim, Daniela, et al.
Publicado: (2019) -
Efficacy of the Therapeutic Game “Trisquel” in the Treatment of Patients With Substance-Related Disorders Randomized Clinical Study
por: Piñón-Blanco, Adolfo, et al.
Publicado: (2022) -
Baseline depressive symptoms as predictors of efficacy and tolerability of the treatment with duloxetine: a network analysis approach
por: Maciaszek, Julian, et al.
Publicado: (2023) -
Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial
por: Zhou, Jiaojiao, et al.
Publicado: (2021)